Drugs / LCAR-M61S
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06472479 | Jul 2024 → Aug 2028 expected | refractory plasma cell neoplasm | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-M61S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06472479 ↗ |
| Modality | Cell therapy | “Biological: LCAR-M61S cells preparation” NCT06472479 ↗ |
| Route | Intravenous | “LCAR-M61S or LCAR-M61D cells intravenous infusion” NCT06472479 ↗ |